Total Payments
$576,692
2024 Payments
$12,773
Companies
56
Transactions
383
Medicare Patients
6,332
Medicare Billing
$3.5M
Payment Breakdown by Category
Research$353,079 (61.2%)
Consulting$144,163 (25.0%)
Travel$36,717 (6.4%)
Other$33,385 (5.8%)
Food & Beverage$8,480 (1.5%)
Education$869.40 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $353,079 | 28 | 61.2% |
| Consulting Fee | $144,163 | 59 | 25.0% |
| Travel and Lodging | $36,717 | 40 | 6.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,495 | 32 | 5.5% |
| Food and Beverage | $8,480 | 219 | 1.5% |
| Honoraria | $1,890 | 1 | 0.3% |
| Education | $869.40 | 4 | 0.2% |
Payments by Type
Research
$353,079
28 transactions
General
$223,614
355 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $334,757 | 18 | $0 (2024) |
| F. Hoffmann-La Roche AG | $68,395 | 54 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $30,900 | 31 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $23,029 | 40 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $20,918 | 29 | $0 (2023) |
| ABBVIE INC. | $20,395 | 12 | $0 (2024) |
| AstraZeneca UK Limited | $16,899 | 20 | $0 (2024) |
| Genentech USA, Inc. | $10,970 | 17 | $0 (2024) |
| PFIZER INC. | $8,729 | 11 | $0 (2024) |
| GlaxoSmithKline, LLC. | $5,715 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,773 | 53 | F. Hoffmann-La Roche AG ($8,159) |
| 2023 | $19,695 | 31 | AbbVie Inc. ($16,992) |
| 2022 | $10,977 | 15 | JAZZ PHARMACEUTICALS INC. ($3,180) |
| 2021 | $12,997 | 16 | F. Hoffmann-La Roche AG ($4,675) |
| 2020 | $45,871 | 29 | F. Hoffmann-La Roche AG ($15,781) |
| 2019 | $77,742 | 73 | AstraZeneca Pharmaceuticals LP ($20,517) |
| 2018 | $98,300 | 65 | Celgene Corporation ($76,073) |
| 2017 | $298,336 | 101 | Celgene Corporation ($240,783) |
All Payment Transactions
383 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $4,930.77 | Research |
| Study: MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | ||||||
| 12/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 12/13/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $50.50 | General |
| 12/13/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.69 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Genentech USA, Inc. | Itovebi (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: BioOncology | ||||||
| 11/19/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), YONSA | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Oncology | ||||||
| 11/12/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $31.99 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: Oncology | ||||||
| 10/25/2024 | ARRAY BIOPHARMA INC | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 10/22/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $43.88 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/07/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $29.57 | General |
| 10/04/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: HORMONE THERAPY | ||||||
| 09/24/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $21.12 | General |
| 09/23/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.36 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: Oncology | ||||||
| 09/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $123.98 | General |
| 08/27/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.41 | General |
| Category: ONCOLOGY | ||||||
| 08/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: Oncology | ||||||
| 07/30/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $16.90 | General |
| Category: Oncology | ||||||
| 07/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABI-007-NSCL-003 | Celgene Corporation | $155,946 | 2 |
| ABI-007-NSCL-004 | Celgene Corporation | $80,901 | 2 |
| ABI-007-NSCL-003 - A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction with nab-Paclitaxel Plus Carboplatin in su | Celgene Corporation | $73,948 | 1 |
| A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction with nab-Paclitaxel Plus Carboplatin in subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC) (ABI-007-NSCL-003) | Celgene Corporation | $15,016 | 2 |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH A PLATINUM AGENT CISPLATIN OR CARBOPLATIN IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1-SELECTED, CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER | F. Hoffmann-La Roche AG | $7,127 | 6 |
| MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | F. Hoffmann-La Roche AG | $6,489 | 2 |
| MY PATHWAY AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMABPERTUZUMAB, ERLOTINIB, VEMURAFENIBCOBIMETINIB, VISMODEGIB , ALECTINIB AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS | F. Hoffmann-La Roche AG | $5,959 | 4 |
| A Phase II, Single Arm, Open-Label, Multicenter, Safety and Tolerability Trial with Nab-Paclitaxel (ABRAXANE ) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment for Subjects with Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC) and an Eastern Cooperative Oncology Group Performance Status of 2 (ABOUND.PS2) (ABI-007-NSCL-004) | Celgene Corporation | $2,866 | 1 |
| ABI-007-NSCL-006 - A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Im | Celgene Corporation | $1,524 | 1 |
| Improving ethnic and racial diversity within clinical trial populations through community recruitment and inclusion initiatives: experience from MyTACTIC | F. Hoffmann-La Roche AG | $951.89 | 1 |
| MyTACTIC: activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers | F. Hoffmann-La Roche AG | $717.36 | 1 |
| ABI-007-NSCL-004 - A Phase II, Single Arm, Open-Label, Multicenter, Safety and Tolerability Trial with Nab-Paclitaxel (ABRAXANE ) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment for Subje | Celgene Corporation | $578.00 | 1 |
| PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC | F. Hoffmann-La Roche AG | $404.50 | 1 |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH A PLATINUM AGENT CISPLATIN OR CARBOPLATIN IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1-SELECTED, CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER, A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH GEMCITABINE CISPLATIN OR CARBOPLATIN FOR PD-L1-SELECTED, CHEMOTHERAPY NAIVE PATIENTS WITH STAGE | F. Hoffmann-La Roche AG | $364.55 | 1 |
| A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | GlaxoSmithKline, LLC. | $284.70 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 1,294 | 12,576 | $844,036 | $444,205 |
| 2022 | 47 | 1,740 | 65,717 | $2.1M | $1.2M |
| 2021 | 43 | 1,690 | 47,772 | $1.5M | $847,964 |
| 2020 | 46 | 1,608 | 49,840 | $1.8M | $982,114 |
Total Patients
6,332
Total Services
175,905
Medicare Billing
$3.5M
Procedure Codes
172
All Medicare Procedures & Services
172 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 7,400 | $511,400 | $319,464 | 62.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 116 | 256 | $73,014 | $32,943 | 45.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 94 | 279 | $105,930 | $24,603 | 23.2% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 26 | 40 | $22,381 | $14,028 | 62.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 63 | 130 | $25,870 | $11,753 | 45.4% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 21 | 95 | $6,680 | $6,811 | 102.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 114 | 535 | $9,927 | $5,454 | 54.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $8,892 | $4,033 | 45.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 112 | 537 | $7,804 | $4,032 | 51.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 95 | 385 | $5,730 | $3,214 | 56.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 59 | 130 | $11,248 | $2,483 | 22.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 38 | $5,358 | $2,056 | 38.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 23 | 42 | $7,812 | $1,924 | 24.6% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 32 | 106 | $3,074 | $1,745 | 56.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 43 | 144 | $9,632 | $1,478 | 15.3% |
| 82533 | Cortisol (hormone) measurement, total | Office | 2023 | 17 | 63 | $1,764 | $1,006 | 57.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 20 | 24 | $4,663 | $1,002 | 21.5% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 15 | 26 | $4,160 | $944.63 | 22.7% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 31 | 56 | $1,344 | $748.16 | 55.7% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 19 | 65 | $1,071 | $569.40 | 53.2% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 17 | 17 | $2,703 | $453.56 | 16.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 35 | 45 | $3,015 | $445.48 | 14.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 15 | 22 | $1,913 | $385.51 | 20.2% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 11 | 56 | $696.00 | $382.49 | 55.0% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2023 | 16 | 185 | $845.00 | $367.74 | 43.5% |
About Dr. David Spigel, M.D
Dr. David Spigel, M.D is a Medical Oncology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427074210.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Spigel, M.D has received a total of $576,692 in payments from pharmaceutical and medical device companies, with $12,773 received in 2024. These payments were reported across 383 transactions from 56 companies. The most common payment nature is "" ($353,079).
As a Medicare-enrolled provider, Spigel has provided services to 6,332 Medicare beneficiaries, totaling 175,905 services with total Medicare billing of $3.5M. Data is available for 4 years (2020–2023), covering 172 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Nashville, TN
- Active Since 07/14/2006
- Last Updated 06/08/2012
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1427074210
Products in Payments
- Abraxane (Drug) $334,716
- IMFINZI (Drug) $21,879
- TECENTRIQ (Biological) $17,492
- Non-Covered Product (Drug) $15,004
- Perjeta (Biological) $11,367
- OPDIVO (Biological) $9,315
- Tecentriq (Biological) $8,985
- Alecensa (Biological) $8,090
- ZYKADIA (Drug) $7,615
- Herceptin (Biological) $5,245
- TAGRISSO (Drug) $4,519
- ILARIS (Biological) $3,560
- ZEPZELCA (Drug) $3,180
- Tarceva (Drug) $2,660
- CANAKINUMAB_ILARIS_IMMUNOLOGY (Biological) $2,320
- TABRECTA (Drug) $2,320
- LIBTAYO (Biological) $2,194
- LUMAKRAS (Drug) $1,947
- MEKINIST (Drug) $1,780
- KEYTRUDA (Biological) $1,449
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Nashville
Dana Thompson, M.d, M.D
Medical Oncology — Payments: $578,344
Medical Oncology $578,344
Johanna Bendell, M.d, M.D
Medical Oncology — Payments: $430,557
Medical Oncology $430,557
Dr. Melissa Johnson, Md, MD
Medical Oncology — Payments: $361,734
Medical Oncology $361,734
Mace Rothenberg, Md, MD
Medical Oncology — Payments: $251,948
Medical Oncology $251,948
Cathy Eng, M.d, M.D
Medical Oncology — Payments: $216,319
Medical Oncology $216,319
Dr. Leora Horn, Md, MD
Medical Oncology — Payments: $203,796
Medical Oncology $203,796